Novo moves into amyloidosis not long after Intellia made a splash here.
And four other potential targets that could make sense for the beleaguered group.
Altimmune’s early-stage obesity hit is impressive, but big pharma has more advanced rivals.
Dolutegravir’s patent expiry will pile on the pressure as Gilead and Merck get on the long-acting bandwagon.
The beleaguered big pharma is under huge pressure to change minds at Wednesday’s investor event.
Acumen is the latest player to take aim at amyloid, but competition is fierce.
Like Aduhelm this long-discontinued amyloid beta MAb reduced brain beta amyloid; so have several other industry projects.
Paying $1.1bn for Heartware five years ago was not the company’s smartest move.
The company hopes that its novel approach in Friedreich’s ataxia could still have legs, but other assets are further ahead.